Supriya Lifescience Limited
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, antiΒhypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Operating margin of 30.9% exceeds Healthcare median (24.8%)
Concerns0
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 9 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ696.00 Cr | β | βΉ188.00 Cr | β | β | 18.9% | 22.1% | 58.0% |
| Mar 2024 | βΉ570.00 Cr | β | βΉ119.00 Cr | β | β | 14.6% | 23.6% | 32.2% |
| Mar 2023 | βΉ461.00 Cr | β | βΉ90.00 Cr | β | β | 12.9% | -13.0% | -40.8% |
| Mar 2022 | βΉ530.00 Cr | β | βΉ152.00 Cr | β | β | 24.7% | 35.5% | 22.6% |
| Mar 2021 | βΉ391.00 Cr | β | βΉ124.00 Cr | β | β | 46.1% | 25.3% | 69.9% |
| Mar 2020 | βΉ312.00 Cr | β | βΉ73.00 Cr | β | β | 49.0% | 12.2% | 87.2% |
| Mar 2019 | βΉ278.00 Cr | β | βΉ39.00 Cr | β | β | 41.5% | 30.5% | 333.3% |
| Mar 2018 | βΉ213.00 Cr | β | βΉ9.00 Cr | β | β | 16.4% | 15.8% | 50.0% |
| Mar 2017 | βΉ184.00 Cr | β | βΉ6.00 Cr | β | β | 13.0% | β | β |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 715 |
| Total Expenses | 457 |
| EBIT / Operating Profit | 258 |
| OPM % | 36% |
| Other Income | 10 |
| Finance Costs | 2 |
| Depreciation & Amortisation | 24 |
| Profit Before Tax | 242 |
| Tax % | - |
| Net Profit / PAT | 182 |
| EPS (βΉ) | 22.66 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Supriya Lifescience Limitedthis co. | βΉ5.94 K Cr | βΉ696.00 Cr | 32.60 | 5.51 | 31.35 | 22.1% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |